Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Ipsen
Sun Yat-sen University
Arcus Biosciences, Inc.
Alliance for Clinical Trials in Oncology
Akeso
Alliance for Clinical Trials in Oncology
Sun Yat-sen University
Summit Therapeutics
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Akeso
AstraZeneca
SWOG Cancer Research Network
Astellas Pharma Inc
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Universitätsmedizin Mannheim
NRG Oncology
J-Pharma Co., Ltd.
NRG Oncology
Canadian Cancer Trials Group
TransThera Sciences (Nanjing), Inc.
Merck Sharp & Dohme LLC
Charite University, Berlin, Germany
Revolution Medicines, Inc.
Sun Yat-sen University
City of Hope Medical Center
Gruppo Oncologico del Nord-Ovest
Genfleet Therapeutics (Shanghai) Inc.
Maimónides Biomedical Research Institute of Córdoba
UNICANCER
Bristol-Myers Squibb
Azienda USL Reggio Emilia - IRCCS
ITM Solucin GmbH
Helsinki University Central Hospital
IFOM ETS - The AIRC Institute of Molecular Oncology
Pfizer
Bristol-Myers Squibb
GERCOR - Multidisciplinary Oncology Cooperative Group
Federation Francophone de Cancerologie Digestive
Ludwig-Maximilians - University of Munich
Charite University, Berlin, Germany
Sun Yat-sen University
Karolinska University Hospital
Alliance for Clinical Trials in Oncology